Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)

Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most patients survive less than 1 year. Aim: The objective...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Oncol
Autors principals: Giommoni, Elisa, Maiello, Evaristo, Vaccaro, Vanja, Rondini, Ermanno, Vivaldi, Caterina, Tortora, Giampaolo, Toppo, Laura, Giordano, Guido, Latiano, Tiziana Pia, Lamperini, Cinzia, Pillozzi, Serena, Boni, Luca, Antonuzzo, Lorenzo, Di Costanzo, Francesco
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8161763/
https://ncbi.nlm.nih.gov/pubmed/34066784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/curroncol28030164
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars